Jibran Ahmed
@jibranahmed1
Followers
87
Following
251
Media
1
Statuses
174
Investigational Cancer Therapeutics, GI Medical Oncology. Opinions mine
Bethesda, MD
Joined April 2010
RT @JIPOEditors: #JIPO received its 1st official #impactfactor = 3.2! .Immunology/Oncology Rank: Q2/Q3. We thank everyone who contributed t….
0
9
0
RT @jitcancer: New #JITC review: Tumor glyco-immunology, glyco-immune checkpoints and immunotherapy .
0
38
0
RT @jitcancer: New #JITC article: Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors….
0
2
0
RT @JIPOEditors: Recent research article by Gouda et al. explores the treatment of malignant #melanoma through the drug combination of #sel….
0
2
0
RT @CamilaBragancaX: Happy to share our review on the complexity of the TME and perspectives on targeting approaches 🎯 Thank you for the st….
0
6
0
First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments | Journal for ImmunoTherapy of Cancer
jitc.bmj.com
Background Tumor-selective oncolytic viral vectors are promising anticancer therapeutics; however, challenges with dosing and potency in advanced/metastatic cancers have limited efficacy and usage....
0
1
4
RT @NatRevDrugDisc: Protein isoform-centric therapeutics: expanding targets and increasing specificity Many genes….
0
40
0
The genomic landscape of 2,023 colorectal cancers | Nature
nature.com
Nature - Whole-genome sequencing of more than 2,000 colorectal carcinoma samples provides a highly detailed view of the genomic landscape of this cancer and identifies new driver mutations.
0
0
1
Fusion Challenges in Solid Tumors: Shaping the Landscape of Cancer Care in Precision Medicine | JCO Precision Oncology
ascopubs.org
Targeting actionable fusions has emerged as a promising approach to cancer treatment. Next-generation sequencing (NGS)–based techniques have unveiled the landscape of actionable fusions in cancer....
0
0
2
RT @JIPOEditors: Review by Feustel et al. examines B7-H3 inhibitors in oncology clinical trials #cancer #clinicaltr….
0
2
0
RT @SilvajDiogo: 🚨 New Review @JIPOEditors . @BlessieNelson. We looked at: .🔎Impact of DCTs on Early Drug Development . 🟢 Benefits | 🚧….
0
2
0
Analysis of 10,478 cancer genomes identifies candidate driver genes and opportunities for precision oncology | Nature Genetics
nature.com
Nature Genetics - Analysis of whole-genome sequencing data from over 10,000 tumor samples spanning 35 cancer types identifies putative driver genes and highlights new therapeutic opportunities.
0
0
4
TIM-3 transcriptomic landscape with clinical and immunomic correlates in cancer - PubMed. @Dr_R_Kurzrock
pubmed.ncbi.nlm.nih.gov
TIM-3, an inhibitory checkpoint receptor, may invoke anti-PD-1/anti-PD-L1 immune checkpoint inhibitor (ICI) resistance. The predictive impact of TIM-3 RNA expression in various advanced solid tumors...
0
0
3
Accurate structure prediction of biomolecular interactions with AlphaFold 3 | Nature
nature.com
Nature - AlphaFold 3 has a substantially updated architecture that is capable of predicting the joint structure of complexes including proteins, nucleic acids, small molecules, ions and...
0
0
1
B cell trajectories influence cancer outcomes | Science
science.org
Two types of B cell in the tumor microenvironment modulate antitumor immunity
0
1
2
RT @MDAndersonNews: In the RE-RAFFLE study led by our Dr. Blessie Nelson, patients who had multiple tumors with RAF alterations were rechal….
0
5
0
RT @BlessieNelson: Read our latest @MDAndersonNews #research with Drs. @VivekSubbiah @DavidHongMD, Meric-Bernstam, Piha-Paul et al on recha….
0
4
0